Roy F. Waldron
Director/Board Member at Starton Therapeutics, Inc.
Profile
Roy F.
Waldron is currently a Director at Starton Therapeutics, Inc. and an Independent Director at HWEL Holdings Corp.
He previously worked as the Chief Intellectual Property Counsel & Senior VP at Pfizer Inc. Waldron received his undergraduate degree from Dartmouth College, his doctorate from Yale University, and his graduate degree from New York University School of Law.
Roy F. Waldron active positions
| Companies | Position | Start |
|---|---|---|
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Director/Board Member | 2019-04-30 |
Former positions of Roy F. Waldron
| Companies | Position | End |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
Training of Roy F. Waldron
| New York University School of Law | Graduate Degree |
| Yale University | Doctorate Degree |
| Dartmouth College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
- Stock Market
- Insiders
- Roy F. Waldron